Filing summary
Entity and period: The supplied filing is Trxade Group, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 30, 2017. It is not identified in the filing as a Scienture Holdings, Inc. report.
Business context
Trxade operated a U.S. business-to-business online pharmaceutical marketplace connecting independent pharmacies with suppliers. It generally earned transaction fees from sellers. Management reported more than 6,650 pharmacy customers and more than 25 supplier customers. Other products and services had not generated revenue. The company discontinued pharmacy-to-pharmacy trading in March 2016, discontinued its INTEGRA consulting business, and shut down its UK ShopRX subsidiary.
On December 31, 2016, Trxade sold Westminster Pharmaceuticals and exited private-label generic drug distribution. Westminster is presented as a discontinued operation.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Continuing-operations revenue | $2,481,866 | $2,912,525 |
| Gross profit | $2,465,504 | $2,722,687 |
| Operating loss | $(984,029) | $(137,070) |
| Loss from continuing operations | $(1,173,108) | $(256,582) |
| Net loss | $(2,760,125) | $(1,117,183) |
| Cash at year end | $14,679 | $78,708 |
| Cash used in continuing operating activities | $(503,529) | $90,386 provided |
- Continuing revenue declined about 15%, which management attributed to a sales mix shift toward brand drugs, which carry lower transaction fees than generics. Gross margin remained approximately 99.3%; the company’s platform revenue is principally fee income.
- General and administrative expense rose to $3,301,903 from $2,504,641. Management cited legal costs and increased staffing. Stock-option expense was $147,630, versus $355,116 in 2015.
- Working capital was negative $1,137,470 at year end. Current assets were $337,124 and current liabilities were $1,474,594. Total liabilities were $1,485,181, compared with a shareholders’ deficit of $1,148,057.
- Debt obligations in the contractual-obligations table totaled $781,350, including $770,763 due within one year. The company reported no traditional bank credit facility and stated that further financing would be needed.
- The auditor and management cited recurring losses and the working-capital deficit as raising substantial doubt about the company’s ability to continue as a going concern.
Material changes, outlook and risks
- Westminster generated $2,966,411 of revenue in 2016 but was unprofitable. The sale included cancellation of debt and issuance of warrants to purchase 1.5 million shares at $0.01 per share. The filing describes the sale as a discontinued operation.
- Management estimated approximately $2.425 million in operating expenses and working-capital needs for the next 12 months. It planned to develop the platform and grow its customer base, and expected to seek additional capital; funding availability and positive operating cash flow were not assured.
- In January 2017, the CEO and president suspended their salaries for four months. The company also disclosed a subsequent $250,000 common-stock financing and issuance of 50,000 shares for legal services in March 2017.
- A $200,000 settlement of a class-action claim alleging unlawful “junk fax” advertising was accrued at year end; final judgment and approval occurred March 17, 2017.
- Key risks include limited cash and continuing financing needs, regulatory restrictions on pharmaceutical distribution and pharmacy-to-pharmacy trading, dependence on suppliers and a buying group, competition from much larger distributors, potential equity dilution, related-party debt, and thinly traded penny-stock shares.
- Disclosure controls and internal control over financial reporting were reported ineffective. The filing identifies weaknesses in written accounting procedures, financial close and reporting, systems integration, staffing, and segregation of duties.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Trxade Group, Inc., despite the request metadata naming Scienture Holdings, Inc.
- Reconcile discontinued-operation losses: the income statement reports $1,587,017, while Note 4 reports $1,784,625 for 2016.
- Reconcile the discontinued-operation investing cash-flow amount: the cash-flow statement shows $78,000 used, while an MD&A summary appears to show $78,000 provided.
- Review the Westminster sale agreement, debt cancellation and warrant terms, and the accounting for the transaction.
- Assess near-term repayment and refinancing needs, available cash, subsequent financing, and the assumptions behind management’s going-concern plans.
- Review potential dilution from outstanding warrants, convertible notes and equity awards, as well as the related-party nature of some borrowings.
- Track whether management remediates the disclosed internal-control weaknesses and maintains timely SEC reporting.